Lucio Rovati graduated Medicine and has a post-graduate specialization in ClinicalPharmacologyat the University of Milan; he completed his training asattendingphysician in Internal Medicine and servedasresearchfellow in the Department of Medical Pharmacology, Chemotherapy and Toxicology of the University of Milan, School of Medicine, for four years.
He founded Rottapharm Biotech in 2014 and currently is Chief Executive Officer and Chief Scientific Officer of the Company.

Besides his experience in internal medicine, Lucio has laboratory skills on in vitro and in vivo pharmacology, particularly of the musculoskeletal, digestive and central nervous systems. However, his most relevant expertise derives from his wide clinical research activity in the direction (including planning, performance and reporting) of clinical research programs and studies for the development of new drugs in rheumatology, gastroenterology/hepatology, gynaecology, bronchopneumology, neurology/psychiatry, cardiology, metabolism and internal medicine.
After holding similar positions at the Universities of Naples and of Parma, DrRovati is at present and since 2003 Invited Professor of Clinical Pharmacology at the University of Milano-Bicocca, School of Medicine, where he is also Coordinator of a Postgraduate Master in Pharmaceutical Medicine.

DrRovati is an active member of several international scientific societies in different disciplines, where he is also included in panels providing advice to the Food and Drug Administration or the European Medicine Agency on the drafting of drug development guidelines.

Finally, he is the author of over 175 full papers in peer reviewed international scientific journals (H-index=42), 15 book chapters and over 400 abstracts. DrRovati has been among the ten Italian scientists with the largest number of publications in clinicalresearch.

No Comments

Sorry, the comment form is closed at this time.